Cytosorbents (CTSO) Net Income towards Common Stockholders (2010 - 2026)
Cytosorbents (CTSO) reported Net Income towards Common Stockholders of -$5.1 million for Q1 2026, down 246.79% on a YoY basis from $3.5 million in Q1 2025, and up 6.69% quarter-over-quarter from -$5.5 million in Q4 2025.
Cytosorbents (CTSO) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Cytosorbents has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$5.1 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 246.79% year-over-year to -$5.1 million; the trailing twelve-month figure through Mar 2026 stood at -$11.8 million (up 26.44% YoY), and the FY2025 full-year result was -$8.2 million, up 60.43% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$5.1 million, up from -$5.5 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $1.9 million in Q2 2025, with the low at -$12.2 million in Q3 2022.
- Historically, Net Income towards Common Stockholders has averaged -$5.6 million across 5 years, with a median of -$5.8 million in 2023.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 661.61% — and 2025, when it jumped 145.34%.
- Cytosorbents' Net Income towards Common Stockholders stood at -$766128.0 in 2022, then sank by 661.61% to -$5.8 million in 2023, then slipped by 29.69% to -$7.6 million in 2024, then advanced by 27.36% to -$5.5 million in 2025, then advanced by 6.69% to -$5.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$5.1 million (Q1 2026), -$5.5 million (Q4 2025), and -$3.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 199.50 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | Cytosorbents | 25.72 Mn | 20.92 Mn | 6.13 Mn | -5.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.13 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | -3.17 Mn |
| Jun 30, 2025 | 1.95 Mn |
| Mar 31, 2025 | -1.48 Mn |
| Dec 31, 2024 | -7.57 Mn |
| Sep 30, 2024 | -2.77 Mn |
| Jun 30, 2024 | -4.29 Mn |
| Mar 31, 2024 | -6.36 Mn |
| Dec 31, 2023 | -5.83 Mn |
| Sep 30, 2023 | -9.19 Mn |
| Jun 30, 2023 | -6.15 Mn |
| Mar 31, 2023 | -7.33 Mn |
| Dec 31, 2022 | -766,128.00 |
| Sep 30, 2022 | -12.20 Mn |
| Jun 30, 2022 | -10.88 Mn |
| Mar 31, 2022 | -8.97 Mn |
| Dec 31, 2021 | -9.31 Mn |
| Sep 30, 2021 | -6.41 Mn |
| Jun 30, 2021 | -4.68 Mn |